ClinConnect ClinConnect Logo
Search / Trial NCT05047068

OCS Heart Perfusion Post-Approval Registry

Launched by TRANSMEDICS · Sep 8, 2021

Trial Information

Current as of July 21, 2025

Active, not recruiting

Keywords

ClinConnect Summary

The OCS Heart Perfusion Post-Approval Registry is a study looking at how well the OCS Heart System works for preserving hearts from donors for heart transplant patients. It aims to gather more information about this system in real-life situations, especially for hearts from donors who have died from brain death (DBD) or donors whose hearts have stopped beating (DCD). This registry is currently active but not recruiting new participants.

To be eligible for this study, you need to be an adult who is receiving a heart transplant using a heart from a DBD or DCD donor that has been preserved with the OCS Heart System. However, you cannot have had another solid organ transplant, like a kidney or liver transplant, or be on kidney dialysis at the time of your heart transplant. If you are interested in this study, it’s important to know that it focuses on collecting information after the heart transplant to ensure the OCS Heart System is effective and safe in real-world settings.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult primary heart transplant recipients of DBD or DCD donor hearts perfused on the OCS Heart System.
  • Recipient Exclusion Criteria:
  • Concurrent (multi-organ transplant) or previous solid organ or bone marrow transplant; or
  • On renal dialysis at time of transplant.
  • Donor Exclusion Criteria (for DCD Donor Hearts only):
  • Warm ischemic time \> 30 minutes (warm ischemic time is defined as: Time from when mean systolic blood pressure (SBP) is \< 50 mmHg or peripheral saturation \< 70% to aortic cross-clamp and administration of cold cardioplegia in the donor).

About Transmedics

TransMedics is a pioneering medical technology company focused on transforming the organ transplant process through innovative solutions. With a commitment to improving patient outcomes, TransMedics has developed advanced organ preservation and transportation systems, notably the Organ Care System (OCS), which enables the preservation and assessment of donor organs in a more physiologically relevant environment. By leveraging cutting-edge technology, TransMedics aims to enhance the viability of organs for transplantation, ultimately expanding the donor pool and improving the lives of patients awaiting transplants. The company’s dedication to research and clinical trials underscores its mission to advance the field of transplantation and contribute to better healthcare solutions.

Locations

Ann Arbor, Michigan, United States

Boston, Massachusetts, United States

Rochester, Minnesota, United States

Boston, Massachusetts, United States

Pittsburgh, Pennsylvania, United States

Valhalla, New York, United States

Durham, North Carolina, United States

Palo Alto, California, United States

Boston, Massachusetts, United States

Seattle, Washington, United States

Nashville, Tennessee, United States

Durham, North Carolina, United States

San Francisco, California, United States

Tampa, Florida, United States

Atlanta, Georgia, United States

Lexington, Kentucky, United States

Minneapolis, Minnesota, United States

Dallas, Texas, United States

Jacksonville, Florida, United States

San Antonio, Texas, United States

Minneapolis, Minnesota, United States

New Haven, Connecticut, United States

Los Angeles, California, United States

Chicago, Illinois, United States

Milwaukee, Wisconsin, United States

Bronx, New York, United States

New York, New York, United States

Dallas, Texas, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials